| October 1 |
FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies |
| October 1 |
Fovea Pharmaceuticals to be Acquired by sanofi-aventis |
| October 1 |
Pfizer Receives Approval From Australian Competition And Consumer Commission (ACCC) For Pending Acquisition Of Wyeth |
| October 1 |
Repros Therapeutics Inc. Provides Update on Proellex |
| October 1 |
Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody |
| October 1 |
Sanofi-Aventis to Buy Abingworth Portfolio Company Fovea |
| October 1 |
MarkMonitor Finds Online Drug Brand Abuse is Growing |
| October 1 |
FDA Warning Letters Caused Dramatic Decline in Sponsored Link Exposures, According to comScore |
| October 1 |
FDA Alert: New USP Standards for Heparin Products Will Result in Decreased Potency |
| October 2 |
Allergan Files Federal Lawsuit to Allow It to Share Relevant Information with the Medical Community on the Safe Use of Botox for Common Therapeutic Off-Label Treatments |
| October 2 |
Avexa Closes ATC's Phase III Trial to Evaluate Data |
| October 2 |
Baxter Receives EMEA Positive Opinion for CELVAPAN H1N1 Pandemic Influenza Vaccine |
| October 2 |
Jeffrey B. Kindler and James S. Tisch to Join New York Fed Board of Directors |
| October 2 |
Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro (escitalopram oxalate) ANDA Patent Litigation |
| October 5 |
Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial |
| October 5 |
SEC Closes Investigation of PharmaNet Development Group and Recommends No Action |
| October 5 |
Pharmaceutical Companies Rebrand Speaker Programs to Meet Changing Political and Regulatory Landscape, Says New Study by Cutting Edge Information |
| October 5 |
Daiichi Sankyo to Leverage Ranbaxy's Presence in Mexico for Marketing and Distribution |
| October 5 |
Physician Smartphone Adoption Rate to Reach 81% in 2012 |
| October 5 |
License to Market Kremezin (drug for chronic renal failure) in Japan |
| October 5 |
CombinatoRx-Derived Combination Drug Candidate, Prednisporin, Acquired by Sanofi-Aventis Through Proposed Acquisition of Fovea Pharmaceuticals |
| October 5 |
Phase 2 Trial Of Rp101 In Late-Stage Pancreatic Cancer Discontinued |
| October 5 |
In the battle against cancer, ?future progress depends on personalisation of healthcare? says AstraZeneca Chief Executive |
| October 6 |
?Pre-Visit Patients? Emerge as New Segment for Advertisers |
| October 6 |
Hydrogen Advertising Teams Up with Local Chapter of National Multiple Sclerosis Society |
| October 7 |
Impax Laboratories Settles Pending Litigation for Flomax |
| October 7 |
Health 2.0 on the Rise - 35% of U.S. Adults Use Social Media for Medical Information |
| October 8 |
Novartis Gains Exclusive Worldwide Rights to PTK 0796, in Phase III Study as Potential First-in-Class IV and Oral Broad-Spectrum Antibiotic |
| October 8 |
IMS Health Forecasts Global Pharmaceutical Market Growth of 4 - 6 Percent in 2010; Predicts 4 - 7 Percent Expansion Through 2013 |
| October 8 |
Cancer Drugs Emerging as Top Driver of Specialty Drug Spending |
| October 9 |
GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations |
| October 9 |
Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for FUSILEV in Advanced Metastatic Colorectal Cancer |
| October 9 |
Vaccinating Boys Against Human Papillomavirus Not Cost-Effective |
| October 9 |
ReachMD XM 160 Announces Two New Radio Programming Series - Featuring the New England Journal of Medicine |
| October 11 |
FDA MedWatch - Relenza (zanamivir) Inhalation Powder must not be reconstituted in liquid formulation or used in any nebulizer or mechanical ventilator |
| October 12 |
Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals |
| October 13 |
Johnson & Johnson Reports 2009 Third-Quarter Results: |
| October 13 |
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt, an FDA-Approved Oral Therapy for Schizophrenia |
| October 13 |
Prosensa and GlaxoSmithKline Form Alliance to Fight Duchenne Muscular Dystrophy |
| October 13 |
Medafor Selects AllOut Marketing as Medical Marketing Partner |
| October 13 |
Shire and Sandoz Settle all Pending Litigation Concerning Adderall XR |
| October 13 |
PhRMA Statement on Senate Finance Committee Vote |
| October 14 |
Dainippon Sumitomo Pharma Co., Ltd. and Sepracor Inc. Announce Successful Tender Offer and Commencement of Subsequent Offering Period |
| October 14 |
Acorda Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Review Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis |
| October 14 |
Elan Corporation PLC Announces Results to Date of Tender Offer for 7¾% Senior Fixed Rate Notes Due 2011 |
| October 14 |
FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets |
| October 14 |
Pfizer Announces Settlement And License Agreement With Mylan Related To Vfend |
| October 14 |
Abbott Reports 16.5 Percent Earnings Growth in Third Quarter; Raises Earnings Guidance for 2009 |
| October 14 |
Galapagos Expands Strategic Alliance in Metabolic Disease with Merck & Co., Inc. |
| October 14 |
CSL Donates 3 Million Doses of Pandemic H1N1 2009 Vaccine to the World Health Organisation (WHO) for Use in Low-Income Countries in this Region |
| October 14 |
Sample Accountability Shows Stepped-Up Focus |
| October 15 |
New FDA Web Page Lists Disposal Instructions for Select Medicines |
| October 15 |
Baxter Reports Double-Digit EPS Growth for Third Quarter 2009 |
| October 15 |
La Jolla Pharmaceutical Company to Seek Stockholder Approval of Dissolution |
| October 15 |
Roche reports further accelerated sales growth in third quarter |
| October 15 |
Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax Sprinkle Capsules |
| October 15 |
Interpublic Aligns Deutsch Inc. and Lowe Worldwide |
| October 15 |
comScore Study Finds the Internet a Key Component in Consumer Research on Prescriptions and Health Conditions |
| October 15 |
Loomis Group Health, Capella Advisors Form Strategic Partnership to Guide Healthcare Companies from Clinical Trials to Marketplace |
| October 15 |
Pfizer Completes Acquisition Of Wyeth |
| October 16 |
AstraZeneca Submits Marketing Authorisation Application to European Union for Vimovo |
| October 16 |
Kentucky Attorney General Conway Announces $14.7 Million Verdict Against Drug Company |
| October 16 |
Court Imposes Record Fine and Forfeiture of $1.3 Billion for Pharmacia & Upjohn Company's Fraudulent Marketing of Bextra |
| October 20 |
Forest Laboratories, Inc. Reports Fiscal Second Quarter 2010 Earnings Per Share of $0.61, Including a Net $0.24 Per Share Charge for One-Time Items |
| October 21 |
Sanofi-Aventis and Wellstat Therapeutics Enter into an Exclusive Worldwide Licensing Agreement for Novel Oral Agent to Treat Type II Diabetes |
| October 21 |
FDA Sends Warning Letter to King Pharmaceuticals Over Embeda Videos |
| October 21 |
Genzyme Reports Third-Quarter Financial Results |
| October 21 |
Account Win for Centron |
| October 22 |
IMS Health Announces 2009 Third-Quarter Results |
| October 22 |
Merck Announces Third-Quarter 2009 Financial Results |
| October 22 |
Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter |
| October 22 |
Centron Wins Agency Of Record Assignments From Strativa |
| October 22 |
Schering-Plough Reports Financial Results for 2009 Third Quarter |
| October 22 |
Novartis delivers strong new product momentum and operational performance in first nine months of 2009 |
| October 22 |
Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49 |
| October 22 |
GE and Lilly Achieve Significant Advancement in Cancer Research |
| October 22 |
Angela Cole Joins Lyonheart As Executive Vice President, Director Of Client Services |
| October 23 |
Merck and Schering-Plough Receive Approval From European Commission for Merger |
| October 23 |
Rituxan (rituximab) - Third case of PML reported, the first case of PML in a patient with rheumatoid arthritis treated with Rituxan who has not previously received treatment with a TNF antagonist |
| October 24 |
New Branding and Creative Services Agency Vertiyo Launches in New York |
| October 26 |
Q3/2009: Merck KGaA Revenues Increase by 2.7% to ? 1.9 Billion |
| October 26 |
S&R Communications Group Reengineers Into S+R Medical Communications And Friday Morning |
| October 26 |
Blue Spoon Consulting Publishes Strategy Innovation for Established Drug Brands |
| October 26 |
Grassley Says Drug Companies Should Disclose Payments, Seeks Greater Transparency |
| October 27 |
Bayer back on the uptrend |
| October 27 |
Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer |
| October 27 |
Changing Behavior Helps Patients Take Medication as Prescribed |
| October 27 |
Vertiyo Creative Services Launches Pharma Division |
| October 27 |
Vertiyo Creative Group Announces Vertiyo Health, New Unit Focused on Pharmaceutical Marketing |
| October 28 |
Neurobiological Technologies Announces Stockholder Approval of Plan of Liquidation and Dissolution |
| October 28 |
FDA Sends Letter to Sanofi-Aventis Regarding Uroxatral Promotion |
| October 28 |
GSK delivers Q3 EPS of 28.5p before major restructuring and dividend of 15p up 7% |
| October 28 |
Use of Antipsychotic Medications by Children and Adolescents Associated With Significant Weight Gain |
| October 28 |
HealthCentral partners with online video startup to create largest health video network |
| October 29 |
Alcon Posts 5.9 Percent Sales Growth for Third Quarter |
| October 29 |
P&G First Quarter Sales and EPS Exceed Expectations |
| October 29 |
AstraZeneca: Third Quarter and Nine Months Results 2009 |
| October 29 |
Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32 |
| October 29 |
Allergan Reports Third Quarter 2009 Operating Results |
| October 29 |
AstraZeneca PLC Third Quarter & Nine Months Results 2009 |
| October 29 |
Novo Nordisk Interim Financial Report for nine months ending 30 September 2009 |
| October 30 |
Pfizer's Board Of Directors Approves Shareholder Advisory Vote On Executive Compensation |
| October 30 |
Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009 |
| October 30 |
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates |
| October 30 |
Geron and FDA Reach Agreement on Clinical Hold |
| October 30 |
States file kickback lawsuit against biotech giant Amgen |
